PharmacoDesign Purchases Illumina Genotyping Solutions for Pharmacogenomics Research
Illumina to Gain Exclusive, Licensed Access to Biomarkers Discovered Through Disease Studies
Under the agreement, Illumina will gain access to biomarkers discovered by PD and will be able to incorporate such markers into proprietary SNP panels under a worldwide, royalty-bearing exclusive license.
PD will study diseases that include obesity, cancer and allergy-induced reactions such as atopy. The company works in partnership with large Korean hospitals to prescribe individualized treatments that utilize diet and "functional foods" in addition to traditional pharmacological approaches.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.